Hunter Holmes McGuire VA Medical Center
Richmond, Virginia, 23249, United States
NCT Number: NCT00487734
This study aims to determine whether testosterone replacement improves insulin sensitivity in non-obese men with low testosterone and the metabolic syndrome. The metabolic syndrome includes three of the following five conditions, 1) an elevated blood pressure (greater than 130/85), 2) a triglyceride level greater than 150 mg/dl, 3) an HDL-cholesterol less than 40 mg/dl, 4) glucose levels greater than 100 mg/dl, and 5) a waist measurement greater than 40 inches.
Looking for future studies?
Notify Me20 year–65 year
Male
Interventional
Phase 4
Richmond, Virginia, 23249, United States
In this proposal, we will examine the relationship between hypogonadism and insulin sensitivity. The strongest relationship between hypogonadism and insulin resistance appears to reside in men with the metabolic syndrome who have a normal BMI. The causal relationship between these two conditions is unknown. Therefore, we propose to determine if testosterone replacement in hypogonadal non-obese men with metabolic syndrome will improve insulin sensitivity. Data obtained from this preliminary investigation, will hopefully result in a hypothesis that can be tested in a larger, more rigorous trial in the future.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(subjects must meet both criteria)
Exclusion criteria
testosterone gel, applied daily. Dosed to achieve testosterone level <500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.
Other names: Androgel
Placebo gel, 2.5g for each gel packet
Time frame: 18 weeks
Time frame: 18 weeks
Time frame: 18 weeks
Time frame: 18 weeks
McGuire Research Institute
Other
Effect of Testosterone Replacement on Insulin Resistance in Hypogonadal, Non-obese Men With Metabolic Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01123278
Body Weight, Endocrine System Diseases
Rome, Italy
View Trial DetailsNCT02240966
Cardio-vascular Disease, Endocrine Gland Neoplasms
Copenhagen, Denmark
View Trial DetailsNCT02102646
Digestive System Diseases, Endocrine System Diseases
Herlev, Denmark
View Trial DetailsNCT07702669
Glucose Metabolism Disorders, Hyperinsulinism
Harbin, Heilongjiang, China
View Trial Details